Nurse Practitioner Independence A JAMA Viewpoint article reports on a March 2025 Nurse Practitioner (NP) Entrepreneurship Summit in Boston in March 2025 identifying barriers and opportunities to NP-owned medical practices. https://t.co/rkzLwhnNYh https://t.co/bxJWptPQK9

• https://buff.ly/21kSPnY

2024 Cardiology Income Survey - CV APP salary has incr 15% from 2019 -23, median=$123K - 50% of APP programs lead by an APP >90% work in outpt. clinics - 2/3 of prgs deploy APPs lipid & prevention management - 2 APPs for every 3 cardiologists https://t.co/gtdm5qN1qD https://t.co/cx2JUcw4U3

• https://buff.ly/Q4C1IGr

German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV

• Outcomes in Patients with Psoriasis Following Apremilast Treatment: Results fro…

Evaluation of pts w/ muscle weakness and elevated muscle enzymes https://t.co/1Yn3OXXEH6 https://t.co/qsTr4U1xV7

• Non-inflammatory mimickers of myositis: a guide for rheumatologists

Diffuse Alveolar Hemorrhage in Rheumatic Disease A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. https://t.co/K1fLo5iHpd

Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/3wdLvkxcAX https://t.co/OqLjv45HXH

• Non-inflammatory mimickers of myositis: a guide for rheumatologists

Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/ruZM3Qftxb

Rheum Survey> 40 yoF RA pt on Prednisone 5 mg/d is at increased risk for ?

RheumNow Live is 3 weeks away, and we can't wait to see you there! Why Attend In Person? ✔ Engage directly with faculty during live Q&A ✔ Network with peers who influence and lead in rheumatology ✔ Experience the energy, pace, and collaboration that can’t be replicated https://t.co/Do8srChyXW

The 2025 Rheumatology Year in Review The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/gjNesm0AWO

ANAs and Autoantibodies https://t.co/PTdXPMCqjP https://t.co/Pbtgaod3uW

• https://buff.ly/meF6Upi

FDA & Administration are deregulating artificial intelligence & promote widespread use, includes use of wearables & other AI-enabled devices. Commissioner Marty Makary updated two guidance docs defining use general wellness devices, clinical decision support software https://t.co/KnkYqCiroa